This site may earn affiliate commissions from the links on this page. Terms of use.

23andMe

Genetic testing firm 23andMe has been using client data in its research program for years, just now it'south putting that data in the hands of a partner. CEO Anne Wojcicki appear today that 23andMe is working with drug maker GlaxoSmithKline (GSK) to develop new drugs and treatments with assist from all that genetic data the company has on file.

The deal is not a surprise and was probably inevitable. GSK has invested around $300 million in 23andMe, which went through a rough patch several years ago when the FDA forced it to revamp all its testing to comply with federal guidelines. 23andMe now shows a more limited set of affliction factors for which there is strong bear witness, whereas before it was rather condescending nearly cartoon conclusions based on your Deoxyribonucleic acid.

Fifty-fifty though information technology doesn't offer information on as many traits in client reports, 23andMe still has a database of 5 million genomes. A significant barrier to inquiry is often getting plenty people to donate samples, merely 23andMe has already taken intendance of that part. Not only that — people paid 23andMe for the privilege. The company has published more than than 100 scientific papers based on its internal research.

The outset major collaboration between GSK and 23andMe will involve studying the LRRK2 gene. Some mutated forms of this cistron may accept a connection to Parkinson'due south Affliction. GSK is working on drugs that might affect LRRK2 activeness, and genetic data from millions of people will assistance researchers determine how the different variants of LRRK2 operate. 23andMe says all genetic information is anonymized to protect your individual privacy.

23andMe customers accept been contributing their data to inquiry for years, just actually partnering with a drug visitor changes the calculation a bit. A drug visitor could potentially create new products from your genetic data and and so toll those drugs and then high that you lot can't afford them. Altruistic genetic information for non-profit research is one thing, but letting commercial entities use it is some other. Fifty-fifty if the results could benefit a lot of people, it doesn't seem entirely off-white for a company to create valuable new patentable products from your genes.

23andMe stresses that its customers can opt-out of making their data available for enquiry at any time. 23andMe has two carve up inquiry consent flags: one for the company'southward internal enquiry and another for sharing data with the company's partners. Presumably, you'll demand to opt-out of that 2d one to avoid inclusion on the GSK partnership. However, in that location's no style to verify that your data doesn't remain in the hands of 23andMe partners if yous opt-out later.

Now read: PCMag's Best Dna Testing Kits of 2022